MedTrace Logo

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

NCT05635149 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-12-02

No results posted yet for this study

Summary

This study was an observational cohort study to investigate the efficacy predictors of fuquinitinib combined with anti-PD-1 monoclonal antibody for third-line treatment and above in Chinese patients with advanced colorectal cancer.

Conditions

  • Colorectal Adenocarcinoma

Interventions

RADIATION

radiotherapy

In radiotherapy group, the modality of radiotherapy was conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) for cancer.

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-06-30
Completion
2023-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05635149 on ClinicalTrials.gov